Money
Briefing: Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab
Strategic angle: UBS maintains a neutral stance on Jasper Therapeutics despite advancements in their Briquilimab treatment.
Editorial Staff
1 min read
Updated 19 days ago
UBS has initiated coverage of Jasper Therapeutics (JSPR) with a neutral rating, reflecting a careful assessment of the company's advancements in Briquilimab.
The decision comes in light of the treatment's progress, yet UBS appears to be weighing potential risks and uncertainties in the therapeutic landscape.
This stance suggests that while Briquilimab shows promise, UBS is not fully convinced of its immediate market impact or the operational capacity of Jasper Therapeutics.